4116-88-5

Usage

Uses

Used in Chelating Applications:
Picolinic acid, 3-ethyl(6CI,7CI,8CI) serves as an effective chelating agent, which is crucial for binding and sequestering metal ions in various chemical processes. This property is particularly valuable in applications where metal ion management is essential, such as in the purification of water or the stabilization of chemical reactions.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, Picolinic acid, 3-ethyl(6CI,7CI,8CI) is utilized as a key component in the synthesis of various drugs. Its unique structure allows it to form the basis of compounds with specific therapeutic properties, contributing to the development of new medications.
Used in Agrochemical Production:
Picolinic acid, 3-ethyl(6CI,7CI,8CI) also finds application in the agrochemical sector, where it is employed in the synthesis of pesticides and other agricultural chemicals. Its role in these products is vital for enhancing crop protection and ensuring agricultural productivity.
Used as an Intermediate in Organic Compounds Production:
Furthermore, Picolinic acid, 3-ethyl(6CI,7CI,8CI) acts as an intermediate in the production of a range of organic compounds. Its ability to participate in various chemical reactions makes it a versatile building block for creating complex organic molecules used in different industries.

Upstream product

• 98491-40-8 3-ethyl-2-pyridinecarboxaldehyde 
• 14159-59-2 2-methyl-3-ethyl-pyridine 
• 1150617-86-9 methyl 3-ethylpicolinate 
• 101870-23-9 (3-ethyl-[2]pyridyl)-methanol 
• 1721-12-6 1-(2-methylpyridin-3-yl)ethanone 
• 174681-86-8 methyl 3-vinylpicolinate 
• 62733-99-7 methyl 3-hydroxypicolinate 
• 157865-84-4 methyl 3-(trifluoromethylsulfonyloxy)-pyridine-2-carboxylate 
• 103030-83-7 acetic acid-(3-ethyl-[2]pyridylmethyl ester) 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HCV NS5A replication complex inhibitors. Part 4.1 optimization for genotype 1a replicon inhibitory activity

A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging f

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.